For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

They are the two drugs of the moment, the weight loss products promising a miraculous solution to obesity and—in data ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Roche plans to invest over $700 million in setting up a new plant in North Carolina and up to $550 million in expanding its Indianapolis diagnostics hub.

Amazon says the company will join other partners including United Parcel Service and the U.S. Postal Service that regularly work alongside Amazon's last-mile delivery network. The private-equity ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is ...